Market Closed -
Nasdaq
01:30:00 18/05/2024 am IST
|
5-day change
|
1st Jan Change
|
18.26
USD
|
-4.40%
|
|
+5.24%
|
+31.84%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
571.9
|
317.9
|
596.3
|
959.4
|
-
|
-
|
Enterprise Value (EV)
1 |
571.9
|
317.9
|
596.3
|
959.4
|
959.4
|
959.4
|
P/E ratio
|
-7.37
x
|
-5.76
x
|
-8.55
x
|
-10.7
x
|
-8.73
x
|
-7.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
363
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
363
x
|
EV / EBITDA
|
-21.9
x
|
-5.42
x
|
-
|
-9.07
x
|
-6.86
x
|
-
|
EV / FCF
|
-23.4
x
|
-6.25
x
|
-11.7
x
|
-10.5
x
|
-7.61
x
|
-10.5
x
|
FCF Yield
|
-4.27%
|
-16%
|
-8.54%
|
-9.49%
|
-13.1%
|
-9.49%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,647
|
41,825
|
43,057
|
52,540
|
-
|
-
|
Reference price
2 |
14.07
|
7.600
|
13.85
|
18.26
|
18.26
|
18.26
|
Announcement Date
|
03/03/22
|
22/03/23
|
19/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
2.64
|
EBITDA
1 |
-
|
-26.15
|
-58.63
|
-
|
-105.8
|
-139.9
|
-
|
EBIT
1 |
-
|
-26.29
|
-58.93
|
-79.94
|
-104.1
|
-135.7
|
-161.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-6,102.85%
|
Earnings before Tax (EBT)
1 |
-
|
-26.29
|
-55.32
|
-69.13
|
-93.77
|
-126.2
|
-151.7
|
Net income
1 |
-9.336
|
-26.29
|
-55.32
|
-69.13
|
-94.24
|
-127.1
|
-144.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-5,459.59%
|
EPS
2 |
-15.72
|
-1.910
|
-1.320
|
-1.620
|
-1.712
|
-2.092
|
-2.330
|
Free Cash Flow
1 |
-
|
-24.41
|
-50.84
|
-50.91
|
-91
|
-126
|
-91
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,446.32%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/08/21
|
03/03/22
|
22/03/23
|
19/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-9.882
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.932
|
-14.83
|
-15.43
|
-13.64
|
-15.02
|
-14.33
|
-16.01
|
-23.96
|
-25.63
|
-22.32
|
-24.78
|
-26.97
|
-30.04
|
-30.5
|
-32.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.93
|
-14.83
|
-15.1
|
-12.51
|
-12.9
|
-11.88
|
-13.27
|
-21.15
|
-22.83
|
-18.19
|
-22.31
|
-24.45
|
-28.49
|
-29.28
|
-31.41
|
Net income
1 |
-9.93
|
-14.83
|
-15.1
|
-12.51
|
-12.9
|
-11.88
|
-13.27
|
-21.15
|
-22.83
|
-18.19
|
-22.33
|
-24.58
|
-28.8
|
-29.28
|
-31.41
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2400
|
-0.3600
|
-0.3600
|
-0.3000
|
-0.3100
|
-0.2800
|
-0.3100
|
-0.4900
|
-0.5300
|
-0.3500
|
-0.4083
|
-0.4383
|
-0.5083
|
-0.4533
|
-0.4700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/03/22
|
05/05/22
|
04/08/22
|
03/11/22
|
22/03/23
|
04/05/23
|
10/08/23
|
07/11/23
|
19/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-24.4
|
-50.8
|
-50.9
|
-91
|
-126
|
-91
|
ROE (net income / shareholders' equity)
|
-
|
-18.3%
|
-19.8%
|
-29.9%
|
-36.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-1.720
|
-1.200
|
-1.170
|
-1.440
|
-1.670
|
-
|
Capex
1 |
-
|
0.66
|
0.56
|
0.77
|
1
|
1
|
2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
75.74%
|
Announcement Date
|
20/08/21
|
03/03/22
|
22/03/23
|
19/03/24
|
-
|
-
|
-
|
Last Close Price
18.26
USD Average target price
24.5
USD Spread / Average Target +34.17% Consensus |
1st Jan change
|
Capi.
|
---|
| +31.84% | 96Cr | | +33.63% | 5.09TCr | | -0.09% | 4.21TCr | | +49.62% | 4.2TCr | | -4.96% | 2.92TCr | | +11.18% | 2.6TCr | | -21.95% | 1.89TCr | | +8.61% | 1.32TCr | | +28.31% | 1.22TCr | | +24.73% | 1.22TCr |
Other Biotechnology & Medical Research
|